Volume 33, Issue 12 (March 2023)                   Studies in Medical Sciences 2023, 33(12): 857-867 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Zaboli Mahdiabadi M, Karami C, Saber E, Kamali M, Orandi A, Dadashi A, et al . EFFECTIVENESS OF MOLNUPIRAVIR IN THE TREATMENT OF PATIENTS WITH COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS. Studies in Medical Sciences 2023; 33 (12) :857-867
URL: http://umj.umsu.ac.ir/article-1-5955-en.html
Assistant Professor, Health in Disasters and Emergencies, Department of Public Health, School of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran (First Corresponding Author) , sadeghahmadi2009@gmail.com
Abstract:   (445 Views)
Background & Aims: Molnupiravir is an oral antiviral drug which is used in the treatment of patients with COVID-19. The purpose of this study was to investigate the effectiveness and safety of molnupiravir in the treatment of patients with COVID-19.
Materials & Methods: A systematic search was conducted in PubMed, Scopus, Cochrane Library, Web of Science, Google Scholar, and Trip database from 2019 to 2022. In addition, a manual search was performed in the sources of primary review and key studies. No restrictions were considered for the language of the studies. Evaluation of the quality of studies was done with Jadad and Newcastle scoring systems. Data analysis was performed using Comprehensive Meta-Analysis version 3 software.
Results: Ten studies with total population of 24221 patients were included in the study. The results of the meta-analysis showed that the risk ratio (RR) between the two groups of molnupiravir and control for the outcome of the mortality rate was 0.67 (0.30-1.49) (P=0.33), for the hospitalization rate was 1.40 (2.50-0.78) (P=0.26), for hospitalization or death was 1.09 (2.69-0.44) (P=0.85), for mechanical ventilation was 0.61 (1.33-0.12) (P=0.11), and for side effects was 0.93 (0.82-1.06) (P=0.29); the difference between means for these outcomes were not significant.
Conclusion: The findings of this study showed that molnupiravir has no effect on reducing mortality rate, hospitalization rate, hospitalization or death, and mechanical ventilation of the patients, although it was safe in the patients.
Full-Text [PDF 801 kb]   (200 Downloads)    
Type of Study: Review article | Subject: عفونی

1. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses 2020;12(4):372. [DOI:10.3390/v12040372] [PMID] [PMCID]
2. Ciotti M, Ciccozzi M, Terrinoni A, Jiang W-C, Wang C-B, Bernardini S. The COVID-19 pandemic. Crit Rev Clin Lab Sci 2020;57(6):365-88. [DOI:10.1080/10408363.2020.1783198] [PMID]
3. Hossain MM, Tasnim S, Sultana A, Faizah F, Mazumder H, Zou L, et al. Epidemiology of mental health problems in COVID-19: a review. F1000Research 2020;9:636-. [DOI:10.12688/f1000research.24457.1] [PMID] [PMCID]
4. Lindholt MF, Jørgensen F, Bor A, Petersen MB. Public acceptance of COVID-19 vaccines: cross-national evidence on levels and individual-level predictors using observational data. BMJ Open 2021;11(6):e048172. [DOI:10.1136/bmjopen-2020-048172] [PMID] [PMCID]
5. Shabestan R, Amani B, Amani B, Akbarzadeh A, Zamani M, Saeidi MR, et al. SARS-CoV-2 breakthrough infection and death in COVID-19 vaccines recipients in North of Iran in 2021. Gen Surg Clin Med 2023;1(2):62-8. [DOI:10.22541/au.166072142.27735652/v1] [PMCID]
6. Delang L, Neyts J. Medical treatment options for COVID-19. Eur Heart J Acute Cardiovasc Care 2020;9(3):209-14. [DOI:10.1177/2048872620922790] [PMID] [PMCID]
7. Vegivinti CTR, Evanson KW, Lyons H, Akosman I, Barrett A, Hardy N, et al. Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials. BMC Infect Dis 2022;22(1):107. [DOI:10.1186/s12879-022-07068-0] [PMID] [PMCID]
8. Niknam Z, Jafari A, Golchin A, Danesh Pouya F, Nemati M, Rezaei-Tavirani M, et al. Potential therapeutic options for COVID-19: an update on current evidence. Eur J Med Res 2022;27:1-15. [DOI:10.1186/s40001-021-00626-3] [PMID] [PMCID]
9. Aschenbrenner DS. Remdesivir approved to treat COVID-19 amid controversy. Am J Nurs 2021;121(1):22-4. https://doi.org/10.1097/01.NAJ.0000767788.97481.65 https://doi.org/10.1097/01.NAJ.0000798996.63395.dc https://doi.org/10.1097/01.NAJ.0000798988.85940.04 https://doi.org/10.1097/01.NAJ.0000911516.31267.67 https://doi.org/10.1097/01.NAJ.0000794244.40800.99 https://doi.org/10.1097/01.NAJ.0000459621.92420.e0 https://doi.org/10.1097/01.NAJ.0000742488.13948.ac https://doi.org/10.1097/01.NAJ.0000798992.09378.14 https://doi.org/10.1097/01.NAJ.0000742484.81331.b2 https://doi.org/10.1097/01.NAJ.0000511560.04823.dd https://doi.org/10.1097/01.NAJ.0000511561.81951.23 https://doi.org/10.1097/01.NAJ.0000476161.13177.75 https://doi.org/10.1097/01.NAJ.0000476160.05553.e2 https://doi.org/10.1097/01.NAJ.0000731640.35662.2c https://doi.org/10.1097/01.NAJ.0000737284.82549.8f [DOI:10.1097/01.NAJ.0000511562.89575.db]
10. Imran M, Kumar Arora M, Asdaq SMB, Khan SA, Alaqel SI, Alshammari MK, et al. Discovery, development, and patent trends on molnupiravir: a prospective oral treatment for COVID-19. Molecules 2021;26(19):5795. [DOI:10.3390/molecules26195795] [PMID] [PMCID]
11. Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, et al. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent Sci 2020;6(5):672-83. [DOI:10.1021/acscentsci.0c00489] [PMID] [PMCID]
12. Painter GR, Natchus MG, Cohen O, Holman W, Painter WP. Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19. Curr Opin Virol 2021;50:17-22. [DOI:10.1016/j.coviro.2021.06.003] [PMID] [PMCID]
13. Lee C-C, Hsieh C-C, Ko W-C. Molnupiravir-a novel oral anti-SARS-CoV-2 agent. Antibiotics 2021;10(11):1294. [DOI:10.3390/antibiotics10111294] [PMID] [PMCID]
14. Vicenti I, Zazzi M, Saladini F. SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. Expert Opin Ther Pat 2021;31(4):325-37. [DOI:10.1080/13543776.2021.1880568] [PMID] [PMCID]
15. Toots M, Yoon J-J, Cox RM, Hart M, Sticher ZM, Makhsous N, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med 2019;11(515):eaax5866. [DOI:10.1126/scitranslmed.aax5866] [PMID] [PMCID]
16. Cully M. A tale of two antiviral targets-and the COVID-19 drugs that bind them. Nat Rev Drug Discov 2021. [DOI:10.1038/d41573-021-00202-8] [PMID]
17. Stevens A, Garritty C, Hersi M, Moher D. Developing PRISMA-RR, a reporting guideline for rapid reviews of primary studies (Protocol). Equator Network 2018. [Google Scholar]
18. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Bmj 2011;343. [DOI:10.1136/bmj.d5928] [PMID] [PMCID]
19. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25(9):603-5. [DOI:10.1007/s10654-010-9491-z] [PMID]
20. Arribas JR, Bhagani S, Lobo SM, Khaertynova I, Mateu L, Fishchuk R, et al. Randomized trial of molnupiravir or placebo in patients hospitalized with Covid-19. NEJM Evidence 2022;1(2):EVIDoa2100044. [DOI:10.1056/EVIDoa2100044]
21. Caraco Y, Crofoot GE, Moncada PA, Galustyan AN, Musungaie DB, Payne B, et al. Phase 2/3 trial of molnupiravir for treatment of Covid-19 in nonhospitalized adults. NEJM Evidence 2022;1(2):EVIDoa2100043. [DOI:10.1056/EVIDoa2100043]
22. Fischer W, Eron JJ, Holman W, Cohen MS, Fang L, Szewczyk LJ, et al. Molnupiravir, an oral antiviral treatment for COVID-19. MedRxiv 2021. [DOI:10.1101/2021.06.17.21258639]
23. Flisiak R, Zarębska-Michaluk D, Rogalska M, Kryńska JA, Kowalska J, Dutkiewicz E, et al. Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance. Pharmacol Rep 2022:1-7. [DOI:10.1101/2022.07.05.22277227]
24. Gleeson S, Martin P, Thomson T, Thind A, Prendecki M, Spensley KJ, et al. Kidney Transplant Recipients and Omicron: Outcomes, effect of vaccines and the efficacy and safety of novel treatments. medRxiv 2022. [DOI:10.1101/2022.05.03.22274524]
25. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. NEJM 2022;386(6):509-20. [DOI:10.1056/NEJMoa2116044] [PMID] [PMCID]
26. Wang L, Berger NA, Davis PB, Kaelber DC, Volkow ND, Xu R. COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022. medRxiv 2022. [DOI:10.1101/2022.06.21.22276724]
27. Wong CK, Au IC, Lau KT, Lau EH, Cowling BJ, Leung GM. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA. 2 wave: a retrospective cohort study. Lancet Infect Dis 2022. [DOI:10.1101/2022.05.19.22275291]
28. Yip CF, Lui GC, Man Lai MS, Wong VW-S, Tse Y-K, Ma BH-M, et al. Impact of the Use of Oral Antiviral Agents on the Risk of Hospitalisation in Community COVID-19 Patients. Available at SSRN 4112160. [Google Scholar]
29. Zheng B, Green AC, Tazare J, Curtis HJ, Fisher L, Nab L, et al. Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe COVID-19 outcomes in non-hospitalised patients: an observational cohort study using the OpenSAFELY platform. medRxiv 2022. [DOI:10.1101/2023.01.20.23284849]
30. Kow CS, Ramachandram DS, Hasan SS. The use of neutralizing monoclonal antibodies and risk of hospital admission and mortality in patients with COVID-19: a systematic review and meta-analysis of randomized trials. Immunopharmacol Immunotoxicol 2022;44(1):28-34. [DOI:10.1080/08923973.2021.1993894] [PMID] [PMCID]
31. Ao G, Li A, Wang Y, Tran C, Qi X. Lack of efficacy for sotrovimab use in patients with COVID-19: A meta-analysis. J Infect 2022. [DOI:10.1016/j.jinf.2022.04.027] [PMID] [PMCID]
32. Crichton ML, Goeminne PC, Tuand K, Vandendriessche T, Tonia T, Roche N, et al. The impact of therapeutics on mortality in hospitalised patients with COVID-19: systematic review and meta-analyses informing the European Respiratory Society living guideline. Eur Respir Rev 2021;30(162). [DOI:10.1183/16000617.0171-2021] [PMID] [PMCID]
33. Gao Y, Yan L, Huang Y, Liu F, Zhao Y, Cao L, et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science 2020;368(6492):779-82. [DOI:10.1126/science.abb7498] [PMID] [PMCID]
34. Gordon CJ, Tchesnokov EP, Schinazi RF, Götte M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J Biol Chem 2021:100770. [DOI:10.1016/j.jbc.2021.100770] [PMID] [PMCID]
35. Kabinger F, Stiller C, Schmitzová J, Dienemann C, Kokic G, Hillen HS, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol 2021;28(9):740-6. [DOI:10.1038/s41594-021-00651-0] [PMID] [PMCID]
36. Singh AK, Singh A, Singh R, Misra A. Molnupiravir in COVID-19: A systematic review of literature. Diabetes Metab. Syndr.: Clin Res Rev 2021;15(6):102329. [DOI:10.1016/j.dsx.2021.102329] [PMID] [PMCID]
37. Tang B, Barnes K, Geers A, Livesey E, Colagiuri B. Choice and the placebo effect: a meta-analysis. Ann Behav Med 2022. [DOI:10.1093/abm/kaab111] [PMID]
38. von Wernsdorff M, Loef M, Tuschen-Caffier B, Schmidt S. Effects of open-label placebos in clinical trials: a systematic review and meta-analysis. Sci Rep 2021;11(1):1-14. https://doi.org/10.1038/s41598-021-96604-0 [DOI:10.1038/s41598-021-83148-6] [PMID] [PMCID]
39. Lai C-C, Wang Y-H, Chen K-H, Chen C-H, Wang C-Y. The Clinical Efficacy and Safety of Anti-Viral Agents for Non-Hospitalized Patients with COVID-19: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Viruses 2022;14(8):1706. [DOI:10.3390/v14081706] [PMID] [PMCID]
40. Lin WT, Hung SH, Lai CC, Wang CY, Chen CH. The impact of neutralizing monoclonal antibodies on the outcomes of COVID‐19 outpatients: A systematic review and meta‐analysis of randomized controlled trials. J Med Virol 2022;94(5):2222-9. [DOI:10.1002/jmv.27623] [PMID] [PMCID]
41. Bown M, Sutton A. Quality control in systematic reviews and meta-analyses. Eur J Vasc Endovasc Surg 2010;40(5):669-77. [DOI:10.1016/j.ejvs.2010.07.011] [PMID]
42. Hernandez AV, Piscoya A, Pasupuleti V, Phan MT, Julakanti S, Khen P, et al. Beneficial and harmful effects of monoclonal antibodies for the treatment and prophylaxis of COVID-19: a systematic review and meta-analysis of randomized controlled trials. Am J Med 2022. [DOI:10.1016/j.amjmed.2022.06.019] [PMID] [PMCID]
43. Amani B, Zareei S, Amani B. Rapid review and meta‐analysis of adverse events associated with molnupiravir in patients with COVID‐19. Br J Clin Pharmacol 2022. [DOI:10.1111/bcp.15449] [PMID] [PMCID]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2023 CC BY-NC 4.0 | Studies in Medical Sciences

Designed & Developed by : Yektaweb